Your medical cannabis journey simplified: find partnered dispensaries, explore pricing options, earn rewards, and get answers to FAQs, all in one spot.
The NIDA-funded investigation will delve into the health-related repercussions of Arkansas’ medical cannabis program, which was initially approved by voters back in 2016. The state has over 79,000 active medical marijuana ID cardholders who, reports show, have purchased more than 60,000 pounds of medical cannabis—equivalent to $400 million in transactions—since the first dispensary opened its doors in May 2019.
ACHI identifies itself as a sovereign health policy center that was formed in 1998. The nonpartisan center’s primary aim is to enhance Arkansans’ health by providing them with cooperative program development, evidence-rooted research, and social matter advocacy.
A Deep Dive Into Cannabis Consumer Data
In order to understand how medical cannabis legalization has had an impact on consumer medical care in Arkansas, the researchers will merge qualifying consumers’ cannabis purchase data with information pulled from insurance claims records, among other data sources. The study will also explore the effects of the ongoing COVID-19 pandemic on the state’s program.
“This is an exciting and unique opportunity for not only our state, but also the country, to investigate the effectiveness of cannabis for therapeutic use,” said the president and CEO of ACHI, Dr. Joe Thompson. “While researchers have gathered scientific evidence on the use of cannabis for the alleviation of symptoms such as pain and anxiety, there is little evidence on how the amount, strain, potency, and method of use affect a person’s health experience.”
Thompson also serves as the study’s co-principal investigator. He will be joined by another co-principal investigator, Teresa J. Hudson, Ph.D., Pharm.D. Hudson is acknowledged as director of the Division of Health Services Research at UAMS and also maintains a position as an associate director at the VA Health Services Research and Development Center for Mental Healthcare and Outcomes Research.
A total of six data sources will be analyzed for the study, including the Arkansas Healthcare Transparency Initiative’s Arkansas All-Payer Claims Database (APCD). “The APCD is a dynamic tool that promotes transparency in healthcare data, and by combining these datasets, our state can assess specific health outcomes, including inpatient and outpatient care visits, emergency visits, opioid usage and new health diagnosis,” explained commissioner for the Arkansas Insurance Department, Alan McClain.
McClain’s department provides oversight for the Arkansas Healthcare Transparency Initiative, which supports the APCD project. According to the investigators who’ve been tasked with carrying out this study, each of the following additional sources will also ensure a more comprehensive analysis:
Medical marijuana dispensary purchase documents
Vital patient records
Emergency room records
Arkansas State Police motor vehicle crash analysis
Arkansas Department of Health medical marijuana patient enrollment data
Rising Tax Revenue From Arkansas’ Medical Cannabis Sales
The state of Arkansas has raked in almost $50 million in tax revenue from medical marijuana sales since the market got into full swing in mid-2019. Of that amount, $25 million was accrued during the last nine months alone. Based on the existing law, all medical cannabis sold at the state’s licensed dispensaries is taxed at 10.5%. Of that, 4% privilege tax is provided to UAMS for the formation of a national cancer institute.
“If you walk into a dispensary and spend $100, you’ll spend $10.50 additionally in state taxes,” said Scott Hardin, who is a member of the Arkansas Medical Marijuana Commission team. He noted that the industry has been going from strength to strength during the coronavirus pandemic. “Those two taxes, we’ve collected just under $50,000,000, 49.6 million to be specific.”
The Arkansas Department of Health issued Executive Orders 20-06 and 20-16 that temporarily allowed the use of telehealth for medical cannabis certifications amid the COVID-19 pandemic. However, those orders ended on March 31, 2021. Since April 1, 2021, physicians have been forbidden from distributing medical marijuana recommendations based on an assessment conducted through telemedicine. Should this change again in the future, the state might see even higher cannabis tax revenue.
Bethan Rose is a cannabis advocate, writer and traveler with no permanent address. Currently based in Bali, she can usually be found curating cannabis content on her hammock.
Cannabis tinctures are relatively new on the scene compared to the long, thousands-year-old history of the cannabis plant itself. It was first recognized for its medicinal use in European medicine in 1839, and by 1851, medicinal cannabis tinctures had made their way into a drug almanac known as the United States Pharmacopeia. Despite prohibition throughout…
Mental health is crucial to our well-being. The National Institute of Mental Health (NIMH) estimates that more than one in five U.S. adults is currently living with a mental health condition. The effort to destigmatize the conversations around mental health is recognized from Mental Health Awareness Month in May to World Suicide Prevention Day in…
Cannabis access has expanded significantly in recent decades. Many states with medical programs have recently adopted recreational legislation allowing anyone 21 years and older to access the plant. This expanded access may leave you wondering if you should bother getting a medical card when you can just purchase cannabis from a recreational store. Medical and…
As cannabis use and accessibility grow nationwide, many universities have established pathways to study the business and science of the plant. Students can research cannabis and its many compounds, pharmacology, cultivation, business, marketing, public policy, and so much more. Beyond cannabis-specific schools like Oaksterdam University and THC University, aspiring cannabis professionals have many options to…
When Piper Lindeen’s son Zach began showing medical issues at just three years old, no one suspected a rare, severe form of epilepsy. Doctors initially didn’t recognize his symptoms as seizures. Eventually, they diagnosed Zach with epilepsy—but by then, his condition had worsened from a few seizures a week to several each day. As it…
The statements made regarding cannabis products on this website have not been evaluated by the Food and Drug Administration (FDA). Cannabis is not an FDA-approved substance and is still illegal under federal law. The information provided on this website is intended for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. It is not intended as medical advice and should not be considered as a substitute for advice from a healthcare professional. We strongly recommend that you consult with a physician or other qualified healthcare provider before using any cannabis products. The use of any information provided on this website is solely at your own risk.